IL23R and colitis: In inflammatory autoimmune conditions, CAR-Tregs targeting the interleukin-23 receptor (IL-23R) effectively suppressed pathogenic Th17 cell responses and attenuated colitis in preclinical models of Crohn’s disease (CD) (84).